ABSTRACT Between 1961 and 1984, 91 patients underwent simultaneous triple valve replacement at the Mayo Clinic. Of the 273 prosthetic valves used, 77% were Starr-Edwards. Perioperative (30 day) mortality was 24% to 27% between 1962 and 1974 and 7% between 1975 and 1983 (p = .17 1, 130-137, 1985. OVER the past 10 years, reports from many centers have defined the early and late results of cardiac valve replacement for most categories of patients.'-9 The outcome of triple valve replacement (aortic, mitral, and tricuspid valve replacement) is less well defined, primarily because of the relatively small numbers of patients who have undergone the operation. With the trend toward conservative tricuspid valve surgery coupled with the development of more predictable methods of valve repair and the declining incidence of rheumatic heart disease in the United States, triple valve replacement is less frequently required than it was previously. Nonetheless, rheumatic heart disease with involvement of multiple valves remains a serious problem in many countries.'0 Accordingly, we report our experience in 91 consecutive patients with rheumatic heart disease who underwent simultaneous triple valve From the Mayo Clinic and Mayo Foundation, Rochester, MN.
OVER the past 10 years, reports from many centers have defined the early and late results of cardiac valve replacement for most categories of patients.'-9 The outcome of triple valve replacement (aortic, mitral, and tricuspid valve replacement) is less well defined, primarily because of the relatively small numbers of patients who have undergone the operation. With the trend toward conservative tricuspid valve surgery coupled with the development of more predictable methods of valve repair and the declining incidence of rheumatic heart disease in the United States, triple valve replacement is less frequently required than it was previously. Nonetheless, rheumatic heart disease with involvement of multiple valves remains a serious problem in many countries.'0 Accordingly, we report our experience in 91 consecutive patients with rheumatic heart disease who underwent simultaneous triple valve replacement at the Mayo Clinic. This is the largest reported series and is particularly notable for the long follow-up period, which spanned 20 years (median duration of follow-up, 7.5 years in perioperative survivors). During this period, major changes in the preoperative, intraoperative, and postoperative practice of valve surgery have occurred. Particular attention has been focused on factors influencing operative risk and late survival, on the causes of late death and late complications, and on the accumulated knowledge derived from this prolonged learning experience. Our earlier experience with triple valve replacement has been reported. 1"' 12 Material and methods
We reviewed the records of all 91 patients with rheumatic heart disease who underwent aortic, mitral, and tricuspid valve replacement during a single operation at the Mayo Clinic from 1962 through 1984. For perspective, this cohort represents only 1% of the total 8359 patients who underwent cardiac valve replacement during the same period. At our institution, the frequency of triple valve replacement has progressively declined: 78 operations were perforned from 1962 through 1974, whereas only 14 triple valve replacements were done on 13 CIRCULATION patients from 1975 through 1984. One patient had undergone triple-valve replacement in 1970, but all three cloth-covered Starr-Edwards valves were replaced in 1984 because of hemolysis.
Clinical data on the 91 patients are summarized in table 1. The severity of preoperative symptoms appears to have changed. Between 1962 and 1974, 50% of patients were in New York Heart Association (NYHA) class IV before surgery and 50% were in NYHA class II or III; of those undergoing operation from 1975 through 1984, only 8% were in NYHA class IV and 92% were in class II or III (p = .024). The predominant valve lesion was classified according to clinical findings, preoperative and intraoperative intracardiac pressure recordings, and operative inspection (table 2) . Preoperatively 86% of patients were in atrial fibrillation, one patient was in paced rhythm, and one patient had episodic sinus arrest. The remaining patients (14%) were in sinus rhythm.
All patients had rheumatic heart disease, and 23 patients had 35 previous cardiac operations. Eight prior operations involved the aortic valve, 24 involved the mitral valve (21 mitral commissurotomies), and three were performed for tricuspid valve disease. Four patients had undergone previous valve replacements (including the patient with a prior triple valve replacement). During the interval of this study, a variety of prosthetic heart valves were used, and these are listed in table 3. Most (77%) were Starr-Edwards prostheses.
Surgical techniques. Methods of extracorporeal circulation and surgical techniques evolved throughout the two decades of this study. All operations were performed through a median sternotomy, and high-flow (2.0 to 2.4 liters/min/m2) hypothermic extracorporeal circulation was used. For the first 84 patients in this series, myocardial protection was achieved by continuous coronary artery perfusion; in the last seven patients, cold potasrium cardioplegia was used during aortic cross-clamping.
Anticoagulation with sodium warfarin was begun in all patients as soon as possible after operation, generally on the second or third postoperative day.
Follow-up. Current information on all patients was obtained by questionnaires to both patients and referring physicians, by telephone contact, or, in patients who had been seen before the end of the present review, by Mayo Clinic records. If possible, the cause of death was ascertained from copies of death certificates or from information supplied by the patient's physician or family.
The diagnosis of thromboembolism was made by a history of stroke, transient cerebrovascular ischemic attacks, or myocardial infarction in patients younger than 45 years or in those with documented normal coronary arteries. Splenic, renal, and pulmonary emboli were diagnosed in a few patients in whom adequate documentation was present, including those in whom a diagnosis was made at autopsy. All patient contacts included specific questions related to possible thromboembolic episodes. Long-term survival. Figure 1 illustrates the cumulative survival of all patients and all 30 day perioperative survivors. The high attrition rate in the first year was not sustained, so that between years 1 and 10 the rate was about 3.5% per year. Overall survival was 64% at 1 year, 55% at 5 years, 40% at 10 years, and 25% at 15 years. For 30 day survivors, late survival was 54% at 10 years and 33% at 15 years. In perioperative (30 day) survivors, the median duration of follow-up was 7.5 years (range, 6 weeks to 20 years). The longest survivor is alive and well (NYHA class II) 20 years after operation, and one patient (previously reported) had a successful pregnancy after triple valve replacement."3
In patients with class II or III disability before surgery, overall S and 10 year survival rates were 73% and 54%, respectively; in contrast, survival rates for patients with preoperative class IV disability were 33% and 25%, respectively (figure 2). As expected, most of the difference between the two groups formed according to preoperative disability were noted in early mortality. In perioperative survivors S and 10 year survival rates were 80% and 59% in those with class II or III disability before surgery compared with 59% and 45% in those with 10. 0.8 We compared the late survival of patients discharged from the hospital after triple valve replacement between 1962 and 1971 with that of a previously reported group of patients at the Mayo Clinic who underwent single valve replacement during the same period (figure 3).7 The survival curves are remarkably similar during the first 10 to 15 postoperative years. For 11 patients undergoing triple valve replacement since 1975, the cumulative 5 year survival rate was 81 %; in comparison, the rate was 52% for patients who underwent triple valve replacement before 1975.
With use of the Cox proportional-hazards model, only preoperative NYHA class IV symptoms and advanced age were related to poor survival (p < .0002 and p < .01, respectively).
Causes of late death. Causes of late death among 67 perioperative survivors are listed in table 4. The most common cause was sudden death (death within 1 hr of symptoms). Three patients had fatal strokes, one patient died of pulmonary embolism presumed to be related to the Starr-Edwards tricuspid prosthesis, and one patient had thrombosis of a Starr-Edwards aortic valve and extension of the thrombus to the left main coronary artery. Progressive congestive heart failure was believed to be the cause of death in 15% of patients, and three other patients died as a result of prosthetic valve dysfunction (including reoperation in one patient). Two Figure 4 illustrates the actuarially determined survival free of thromboembolism. Only the first thromboembolic event was considered in the actuarial analysis, but all first episodes were included, regardless of severity. Embolism-free survival rates were 86% at 1 year, 70% at 5 years, and 43% at 10 and 12 years after surgery.
Twelve patients in this series required permanent o 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Years after surgery pacemakers. In two patients, permanent pacemaker implantation was performed in the perioperative period. In the other 10 patients, permanent pacemakers were required for symptomatic bradyarrhythmias, and the most frequent indication was atrial fibrillation with complete heart block or symptomatic pauses. In these patients, the interval from operation to pacemaker implantation ranged from 3 to 18 years (mean, 9.4 years) after initial valve replacement. Functional outcome. Figure 5 illustrates the functional class of the 29 patients (32% of the total population) still alive at the end of follow-up. The median duration of follow-up was 10.7 years. Clinical improvement was striking. Before surgery 96% of patients Were NYHA class III or IV, and at the time of last follow-up 79% of patients were NYHA class I or II.
Discussion
At our institution, the frequency of triple valve replacement has decreased markedly during the past dec- 4 6 2 Some patients had more than one complication.
AIncluding two with hemorrhage. Operative mortality was 34% in patients with pure tricuspid insufficiency, which is significantly higher than the 13% in patients with mixed tricuspid valve disease. In some of the former group, tricuspid insufflciency might have been functional and a manifestation of poor right ventricular function and pulmonary hypertension,27 whereas in patients with mixed disease, tricuspid valve involvement presumably was organic.
Late mortality. Late attrition that after the first postoperative year is relatively small but consistently observed. The overall 5, 10, and 15 year survival rates in this series are similar to rates in other studies. Five year survival rates were reported to range from 42% to 67%,'7 1921 23 10 year rates from 37% to 55%,2 23 An important finding of this review was the significant incidence of bradyarrhythmias requiring permanent pacemaker implantation. The causes are multifactorial, including intraoperative damage to the conduction system, fibrosis secondary to chronic compressive effects of the rigid mitral and tricuspid sewing ring, and rheumatic heart disease. During the course of this experience, indications for permanent pacing have become more liberal, and this change could have contributed to the late incidence of permanent pacemaker implantation. Nonetheless, all the patients undergoing pacemaker implantation, except one in whom implantation was performed intraoperatively, did have symptoms of major conduction disease.
Our data suggest that late survivors after valve replacement should be regularly evaluated (including Holter monitoring) for ventricular arrhythmias and conduction disturbances.34 A high index of suspicion should be maintained, since the presentation of conduction disease and arrhythmias may be subtle.
Currently, we advocate implantation of permanent epicardial leads at the time of triple valve replacement to avoid a pacemaker lead being placed across the prosthetic tricuspid valve.
Thromboembolism. Comparing the incidence of thromboembolism in different series is difficult. 35 36 The incidence varies widely and depends on criteria used to define a thromboembolic event, frequency and accuracy of follow-up data, type of valve used, and the inherent limitations of retrospective analyses.35 Clearly, thromboembolism is a frequent cause of serious morbidity and mortality after triple valve replacement; the embolic rate of 12.3 events per 100 patient-years in this study is similar to the 11.4 events per 100 patientyears reported by Macmanus et al.'9 Embolism-free survival at 5 years is 70%, similar to that in other early series of single valve replacements with Starr-Edwards valves.2 4 7-9, 313 The 10 year embolism-free rate is lower and the overall embolic rate higher in patients with three valves than in those with single or double valves.2 7 9 3 7 Several reports have documented a recent reduction in incidence of thromboembolism after valve replacement.2 3 5 6 This may be related to improved methods of maintaining anticoagulation, the addition of antiplatelet agents, earlier operation, improved prosthetic valve design, or a combination of these.
Valve durability. The durability of the Starr-Edwards valve is underscored by the relatively low incidence of reoperation or death due to prosthetic valve dysfunction. The vulnerability of the mechanical prosthesis (particularly tilting-disk prostheses) in the tricuspid position to thrombosis and sudden malfunction has been noted by others.'2' 23. 4043 Five of the 11 valves requiring replacement were in the tricuspid position, and two deaths were due to tricuspid valve thrombosis, an indication that the Starr-Edwards valve is also prone to dysfunction in this position. There are lessons to be derived from this experience. The use of certain prosthetic valves subsequently found to be associated with a high incidence of problems, for example, the Braunwald-Cutter valve and the cloth-covered Starr-Edwards valve, was discontinued later. Improved techniques for tricuspid annuloplasty have undoubtedly diminished the requirement for tricuspid valvular replacement, and when replacement is still found to be necessary, the knowledge that mechanical prostheses tend to do less well in the tricuspid position than in the mitral or aortic position has led to our current policy of using tissue valves for tricuspid valve replacement.
Symptomatic status. The symptomatic status of patients currently alive is encouraging, and the results of comparisons with preoperative status are quite striking. That 79% of patients after a median duration of follow-up of almost 11 years should be in NYHA class I or II is indicative of the value of the procedure, but these results must be construed in light of the fact that 68% were dead at the time of last follow-up. Furthermore, the impact of surgery on these patients is not confined to the procedure of triple valve replacement. Twenty-three patients had had prior cardiac surgical procedures, and some of these patients were still alive and well more than 30 years after an initial mitral commissurotomy.
In conclusion, in our experience operative mortality for patients undergoing triple valve replacement appears to have been reduced. The frequency of use of the procedure has declined markedly in parallel with an increase in the number of patients undergoing double valve replacement and tricuspid annuloplasty. Early and late results can be expected to improve further if operative intervention is carried out before the onset of class IV symptoms. The frequency of late sudden death is of concern, and periodic evaluation for ventricular arrhythmias and conduction disturbances is recommended. The increased rate of thromboembolism and the significant incidence of bleeding after triple valve replacement with mechanical prostheses mandate meticulous anticoagulation for life.
Because most late mechanical prosthetic failures were of valves in the tricuspid position, the use of tricuspid annuloplasty when possible is recommended; if tricuspid valve replacement is required, a biologic prosthesis should be considered. CIRCULATION 
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In patients who survive the perioperative period, the favorable long-term outcome and excellent symptomatic relief after triple valve replacement establish a continued role for the procedure in patients with severe multivalvular rheumatic heart disease.
